Acute and Sustained Reductions in Loss of Meaning and Suicidal Ideation Following Psilocybin-Assisted Psychotherapy for Psychiatric and Existential Distress in Life-Threatening Cancer
Open accessThe DOI matches its Crossref record; 81 of the 81 references it cites were found in a registry or an index.
Abstract
People with advanced cancer are at heightened risk of desire for hastened death (DHD), suicidal ideation (SI), and completed suicide. Loss of Meaning (LoM), a component of demoralization, can be elevated by a cancer diagnosis and predicts DHD and SI in this population. We completed a randomized controlled trial in which psilocybin-assisted psychotherapy (PAP) produced rapid and sustained improvements in depression, demoralization, and hopelessness in people with cancer. Converging epidemiologic and clinical trial findings suggests a potential antisuicidal effect of this treatment. To probe our hypothesis that PAP relieves SI through its beneficial impacts on depression and demoralization (LoM in particular), we performed secondary analyses assessing within- and between-group differences with regard to LoM and an SI composite score. Among participants with elevated SI at baseline, PAP was associated with within-group reductions in SI that were apparent as early as 8 h and persisted for 6.5 months postdosing. PAP also produced large reductions in LoM from baseline that were apparent 2 weeks after treatment and remained significant and robust at the 6.5 month and 3.2 and 4.5 year follow-ups. Exploratory analyses support our hypothesis and suggest that PAP may be an effective antisuicidal intervention following a cancer diagnosis due to its positive impact on hopelessness and demoralization and its effects on meaning-making in particular. These preliminary results implicate psilocybin treatment as a potentially effective alternative to existing antidepressant medications in patients with cancer that are also suicidal, and warrant further investigation in participants with elevated levels of depression and suicidality.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“One of these shows a sustained reduction in demoralization, 62 while the other presents the clinical response rates for depression and anxiety. 61”
From The revival of psilocybin between scientific excitement, evidence of efficacy, and real-world challenges (2024) · cites this paper as [62]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Only two long-term 4.5-year follow-up studies are available, involving 4 and 14 patients, respectively. 61,62”
From The revival of psilocybin between scientific excitement, evidence of efficacy, and real-world challenges (2024) · cites this paper as [62]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“with only two secondary analyses providing data on 4.5 years of follow-up, 61,62”
From The revival of psilocybin between scientific excitement, evidence of efficacy, and real-world challenges (2024) · cites this paper as [62]
The cited source says what the claim attributes to it.
In the citing paper
“Open-label studies 25,39,57,78-81 and two followup analyses 61,62 supported the overall positive findings of RCTs.”
From The revival of psilocybin between scientific excitement, evidence of efficacy, and real-world challenges (2024) · cites this paper as [62]
The cited source says what the claim attributes to it.
In the citing paper
“Secondary analyses of these data 4.5 years later found that psilocybin therapy was also associated with reductions in suicidal ideation that were apparent post-intervention and persisting as well as with large reductions in loss of meaning persisting up to 4.5 years”
From Psychosocial and Integrative Oncology: Interventions Across the Disease Trajectory. (2023) · cites this paper as Ross et al. 2021
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders.
Widiger, T. A. (2000) · Encyclopedia of Psychology, Vol. 3. · doi:10.1037/10518-009 · Cited by 19,744
Psychometric properties of the Beck Depression Inventory: Twenty-five years of evaluation
Beck, A. T., Steer, R. A., & Carbin, M. G. (1988) · Clinical Psychology Review · doi:10.1016/0272-7358(88)90050-5 · Cited by 11,696
World Health Organization classification of tumors
Kleihues, P., & Sobin, L. H. (2000) · Cancer · doi:10.1002/1097-0142(20000615)88:12<2887::aid-cncr32>3.0.co;2-f · Cited by 2,377
Suicide and suicidal behaviour
Turecki, G., & Brent, D. A. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00234-2 · Cited by 2,338
Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675513 · Cited by 2,201
Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675512 · Cited by 1,698
Self-citationPsychedelics promote structural and functional neural plasticity
Ly, C., Greb, A. C., Cameron, L. P., Wong, J. M., Barragan, E. V., Wilson, P. C., Burbach, K. F., Soltanzadeh Zarandi, S., Sood, A., Paddy, M. R., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.05.022 · Cited by 1,207
Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer
Grob, C. S., Danforth, A. L., Chopra, G. S., Hagerty, M., McKay, C. R., Halberstadt, A. L., & Greer, G. R. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.116 · Cited by 1,206
Depression, Hopelessness, and Desire for Hastened Death in Terminally Ill Patients With Cancer
Breitbart, W. (2000) · JAMA · doi:10.1001/jama.284.22.2907 · Cited by 1,110
Psilocybin with psychological support for treatment-resistant depression: six-month follow-up
Carhart-Harris, R. L., Bolstridge, M., Day, C. M. J., Rucker, J., Watts, R., Erritzoe, D. E., Kaelen, M., Giribaldi, B., Bloomfield, M., Pilling, S., et al. (2018) · Psychopharmacology · doi:10.1007/s00213-017-4771-x · Cited by 970
Research works printed but not linked: 2
- Robinson, 2015, A systematic review of the demoralization syndrome in individuals with progressive disease and cancer: a decade of research, J. Pain Symptom Manage., 49, 595, 10.1016/j.jpainsymman.2014.07.008 · DOI · Paper page
- Ross, 2021, Psilocybin
Cited by
Items 101–150 of 150
Updates in palliative care of gynecologic oncology patients
Khoo, T., Karlin, D., & Pietras, C. J. (2024) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0000000000001000 · Cited by 1
Is there mush-room to improve the environmental sustainability of psilocybin production?
Lanham, L., McTaggart, A. R., & Falconer, J. R. (2025) · Journal of CO2 Utilization · doi:10.1016/j.jcou.2025.103137 · Cited by 1
Vinarcsik, L., Smoller, C., & Grossberg, G. T. (2025) · Drugs & Aging · doi:10.1007/s40266-025-01221-5 · Cited by 1
SUBJECTIVE EXPERIENCES OF CLASSIC PSYCHEDELIC SUBSTANCES USERS
Bienemann, B. (2022) · doi:10.17771/pucrio.acad.59337 · Cited by 1
Breeksema, J. J. (2024) · University of Groningen research database (University of Groningen / Centre for Information Technology) · doi:10.33612/diss.912040905 · Cited by 1
Cho, M., Rosenbaum, D., Schneider, E., & Hales, S. (2024) · Journal of Palliative Medicine · doi:10.1089/jpm.2023.0668 · Cited by 1
Zeifman, R. J. (2024) · doi:10.32920/26052859.v1 · Cited by 1
Self-citationPsychedelic-assisted psychotherapy: The need to monitor adverse events
Schruers, K. R. J., & Leibold, N. K. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811251340929 · Cited by 1
Machado, T. L. G. N., Rodrigues, A. S. L., & Costa, J. N. (2025) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253251397590 · Cited by 1
Psilocybin-Assisted Psychotherapy in Palliative Care
Ross, S., & Bossis, A. P. (2022) · Oxford University Press eBooks · doi:10.1093/med/9780197583838.003.0042
Self-citationVelasquez, J. F., Mantilla‐Manosalva, N., Cuellar‐Valencia, L., Giraldo‐Moreno, S., Maya-Róldan, M. A., & Correa‐Morales, J. E. (2023) · Medicina Paliativa · doi:10.20986/medpal.2023.1354/2022
Palliative care for people living with heart and lung disease
(2023) · Frontiers research topics · doi:10.3389/978-2-83251-419-1
JSE 36:4 Winter 2022 Full Issue
Laythe, B. R. (2023) · Journal of Scientific Exploration · doi:10.31275/20222881
Psilocybin-Based Breakthroughs in Natural Medicine
Harmony, D., Judy, F., & Dochniak, M. J. (2023) · Case Reports and Reviews · doi:10.33425/2693-1516.1021
EFEITOS PSICOLÓGICOS DA PSILOCIBINA EM PORTADORES DE CÂNCER TERMINAL: Uma revisão de escopo
Silva, L. H. F., da Mata, J. A. L., Stefanello, S., Rocha, C. M. F., & Luiz, F. F. (2024) · Psicologia e Saúde em Debate · doi:10.22289/10.22289/2446-922x.v10n1a3
The Role of Rapid-Acting Antidepressants in Suicidal Crisis Management
Lengvenytė, A., Sarchiapone, M., Iosue, M., & Courtet, P. (2024) · Cambridge University Press eBooks · doi:10.1017/9781009067287.016
Introduction to the EMBARK Approach
Brennan, B., & Belser, A. (2024) · Oxford University Press eBooks · doi:10.1093/9780197762622.003.0003
Brennan, B., & Belser, A. (2024) · Oxford University Press eBooks · doi:10.1093/9780197762622.003.0006
Bringing It Home and Carrying It Forward
Brennan, B., & Belser, A. (2024) · Oxford University Press eBooks · doi:10.1093/9780197762622.003.0009
Considerations Prior to Meeting With a Participant
Brennan, B., & Belser, A. (2024) · Oxford University Press eBooks · doi:10.1093/9780197762622.003.0005
INTRODUCTION: A New Approach for the Whole Person
Brennan, B., & Belser, A. (2024) · Oxford University Press eBooks · doi:10.1093/9780197762622.003.0001
Choosing Suggested Integration Goals
Brennan, B., & Belser, A. (2024) · Oxford University Press eBooks · doi:10.1093/9780197762622.005.0004
Working Within the EMBARK Domains Cheat Sheet
Brennan, B., & Belser, A. (2024) · Oxford University Press eBooks · doi:10.1093/9780197762622.005.0003
Brennan, B., & Belser, A. (2024) · Oxford University Press eBooks · doi:10.1093/9780197762622.003.0007
Brennan, B., & Belser, A. (2024) · Oxford University Press eBooks · doi:10.1093/9780197762622.005.0002
An Overview of Psychedelic-Assisted Therapy
Brennan, B., & Belser, A. (2024) · Oxford University Press eBooks · doi:10.1093/9780197762622.003.0002
Personal Care for the Therapist
Brennan, B., & Belser, A. (2024) · Oxford University Press eBooks · doi:10.1093/9780197762622.005.0001
Brennan, B., & Belser, A. (2024) · Oxford University Press eBooks · doi:10.1093/9780197762622.003.0008
Brennan, B., & Belser, A. (2024) · Oxford University Press eBooks · doi:10.1093/9780197762622.002.0004
EMBARK Mechanisms of Change in the Treatment of Depression
Brennan, B., & Belser, A. (2024) · Oxford University Press eBooks · doi:10.1093/9780197762622.003.0004
Exploring psilocybin’s role in mental health and palliative medicine: a path to improved well-being
Umbacia, M. A., León, M., Quintero, J.-M., Castro, L.-M., Páez, V., Dodd, S., & Bustos, R. (2025) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2025.2488786
Psychedelics for Depression: Between Hopes and Uncertainties
Suppes, T. M., & Fradet, M. (2025) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.20250005
Research Progress on Depression Syndrome in Patients with Colorectal Cancer
吴, 迪. (2025) · Nursing Science · doi:10.12677/ns.2025.145116
Humphreys, J., Lukas, L. A., Beaussant, Y., Fischer, S. M., Araujo, T. S., Spence, D., Harris, J. P., Anderson, B. T., & Grob, C. S. (2025) · Oxford University Press eBooks · doi:10.1093/med/9780197760864.003.0002
de Moraes, M. Q. O., Gomes, B. B., Gomes, L. M., Requeijo, N. M., & Ouriques, N. D. S. (2025) · doi:10.22533/at.ed.7161525180610
Les « champignons magiques » : des alliés en soins palliatifs ?
Shen, A., Côté, A., Lamanque, P., Stephan, J.-F., & Farzin, H. (2025) · Cahiers francophones de soins palliatifs · doi:10.7202/1120298ar
Rosa, W. E., Napolitano, S., McAndrew, N., Jenkins, B., Lichtenthal, W. G., Applebaum, A. J., BREITBART, W. S., & Agrawal, M. (2025) · Psychedelic Medicine · doi:10.1177/28314425251363983
Colelli, J. (2024) · PhilPapers (PhilPapers Foundation)
Whitmore, H., Mangini, M., Leutwyler, H. C., & Anderson, B. T. (2026) · Palliative Medicine Reports · doi:10.1177/26892820251401798
Magnani, L., Ghirotto, L., Fesce, F., Re, T. S., Tanzi, S., Amerio, A., & Costanza, A. (2026) · BMJ Supportive & Palliative Care · doi:10.1136/spcare-2025-005689
Kelly, C. M., Fradet, M., Bostian, C. M., Donnelly, A. J., Ellis, S., Ostacher, M. J., Aaronson, S. T., & Suppes, T. M. (2026) · Journal of Affective Disorders · doi:10.1016/j.jad.2026.122063
Tsang, V. W. L., Kryskow, P., Watler, C., Allard, P., & Dames, S. (2026) · Frontiers in Public Health · doi:10.3389/fpubh.2026.1767215
de Oliveira, A. B. P., & Hein, M. (2026) · L Encéphale · doi:10.1016/j.encep.2026.04.004
Albertyn, C. P., Richard, J., Shore, R., & Carlson, L. E. (2026) · Psychedelics · doi:10.1016/j.psyche.2026.100032
Psychedelika in der Palliativmedizin
Adolphi, H., Jungaberle, A., & Kärtner, L. (2026) · Elsevier eBooks · doi:10.1016/b978-3-437-21293-2.00017-4
Psychedelics and suicidality: A double-edged sword - risks, mechanisms, and moving forward
Mallevays, M., & Berkovitch, L. (2026) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2026.113878
Psilocybin as a Potential Therapy for Managing Depression and Anxiety in Cancer Patients
Kariim, A. C. N. E., Nurcahya, N. T., Nurcahya, N. T., Sungkono, A. C., Sherryn, S., & Safitri, Y. (2026) · Journal of Innovative and Creativity (Joecy) · doi:10.31004/joecy.v6i1.8905
Clinical Evidence on Psilocybin and Its Representation in Media Reporting: A Systematic Review
Madden, K., Flood, B., Kashir, I., Ahmad, R., Ali, H., Petranker, R., MacKillop, J., & Adili, A. F. (2026) · JAMA Network Open · doi:10.1001/jamanetworkopen.2026.38843
Pitis, A., Nikoloudi, M., Stefanis, N., & Mystakidou, K. (2026) · Journal of Pain & Palliative Care Pharmacotherapy · doi:10.1080/15360288.2026.2756950
Metadata
- Authors
- Ross, S., Agin-Liebes, G., Lo, S., Zeifman, R. J., Ghazal, L., Benville, J., Franco Corso, S., Bjerre Real, C., Guss, J., Bossis, A., & Mennenga, S. E.
- Affiliations
- NYU Langone Health (US)
- San Francisco General Hospital (US)
- Pacific University Oregon (US)
- Toronto Metropolitan University (CA)
- Columbia University , , , , ,
- Memorial Sloan Kettering Cancer Center , , , ,
- Corresponding author
- Ross, Stephen
- Venue
- ACS Pharmacology & Translational Science
- Publisher
- American Chemical Society (ACS)
- Published
- 2021-03-18
- Volume
- 4
- Issue
- 2
- Pages
- 553-562
- ISSN
- 2575-9108 (ISSN-L)
- PMC
- PMC8033770
- OpenAlex
- W3138429576
- Cited by
- 139
- References
- 80
- Citations by year
- 2026: 14 · 2025: 33 · 2024: 40 · 2023: 22 · 2022: 24 · 2021: 6
- FWCI
- 15.69
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- Locations
- ACS Pharmacology & Translational Science (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Riverstyx Foundation
- Clinical and Translational Science Institute, New York University
- Heffter Research Institute
- National Institute on Drug Abuse (T32DA007294, T32DA007250)
- National Cancer Institute (P30CA008748)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Palliative and Oncologic Care
- Health Sciences › Medicine › Oncology › Cancer survivorship and care
- Keywords
- psilocybin-assisted therapy, suicidal ideation, meaninglessness, demoralization, advanced cancer, depression, hopelessness, meaning-making, psychedelic therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.